Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angioplasty, Balloon, Coronary | 17 | 2012 | 1724 | 2.480 |
Why?
|
| Myocardial Infarction | 33 | 2022 | 11476 | 1.710 |
Why?
|
| Acute Coronary Syndrome | 15 | 2024 | 2194 | 1.600 |
Why?
|
| Platelet Aggregation Inhibitors | 21 | 2024 | 2746 | 1.480 |
Why?
|
| Coronary Circulation | 12 | 2013 | 1611 | 1.430 |
Why?
|
| Thrombolytic Therapy | 9 | 2011 | 2055 | 1.190 |
Why?
|
| Morpholines | 3 | 2014 | 581 | 1.020 |
Why?
|
| Thiophenes | 3 | 2014 | 569 | 0.940 |
Why?
|
| Fibrinolytic Agents | 10 | 2021 | 2075 | 0.800 |
Why?
|
| Electrocardiography | 12 | 2014 | 6387 | 0.780 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 10 | 2024 | 284 | 0.760 |
Why?
|
| Ticlopidine | 6 | 2017 | 730 | 0.750 |
Why?
|
| Coronary Angiography | 14 | 2021 | 4506 | 0.660 |
Why?
|
| Aspirin | 10 | 2023 | 3129 | 0.650 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2014 | 577 | 0.610 |
Why?
|
| Stents | 6 | 2021 | 3177 | 0.580 |
Why?
|
| Hemorrhage | 9 | 2024 | 3422 | 0.530 |
Why?
|
| Intercostal Nerves | 1 | 2013 | 28 | 0.440 |
Why?
|
| Coronary Occlusion | 2 | 2014 | 304 | 0.440 |
Why?
|
| Drug Therapy, Combination | 13 | 2023 | 6304 | 0.430 |
Why?
|
| Myocardial Ischemia | 3 | 2016 | 2133 | 0.420 |
Why?
|
| No-Reflow Phenomenon | 1 | 2012 | 16 | 0.410 |
Why?
|
| Denervation | 1 | 2013 | 265 | 0.410 |
Why?
|
| Coronary Artery Disease | 5 | 2021 | 6505 | 0.400 |
Why?
|
| Vitamin K | 1 | 2014 | 313 | 0.400 |
Why?
|
| Adenosine | 2 | 2016 | 805 | 0.390 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2011 | 445 | 0.370 |
Why?
|
| Bilirubin | 1 | 2013 | 436 | 0.370 |
Why?
|
| Myocardial Reperfusion | 2 | 2002 | 339 | 0.370 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2010 | 578 | 0.360 |
Why?
|
| Anticoagulants | 5 | 2021 | 4795 | 0.360 |
Why?
|
| Drug-Eluting Stents | 1 | 2017 | 681 | 0.360 |
Why?
|
| Atrial Fibrillation | 3 | 2021 | 5114 | 0.350 |
Why?
|
| Polymers | 1 | 2017 | 1617 | 0.330 |
Why?
|
| Enoxaparin | 2 | 2008 | 391 | 0.320 |
Why?
|
| Cryosurgery | 1 | 2013 | 474 | 0.300 |
Why?
|
| Platelet Count | 2 | 2011 | 782 | 0.300 |
Why?
|
| Coronary Thrombosis | 1 | 2011 | 440 | 0.300 |
Why?
|
| Adenosine Monophosphate | 2 | 2021 | 231 | 0.290 |
Why?
|
| Heptanoic Acids | 1 | 2009 | 344 | 0.290 |
Why?
|
| Pravastatin | 1 | 2009 | 392 | 0.290 |
Why?
|
| Peptides | 4 | 2010 | 4353 | 0.270 |
Why?
|
| Hyperemia | 1 | 2008 | 225 | 0.270 |
Why?
|
| Treatment Outcome | 25 | 2023 | 64681 | 0.270 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 361 | 0.270 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 1780 | 0.270 |
Why?
|
| Hospital Mortality | 6 | 2012 | 5295 | 0.260 |
Why?
|
| Thrombectomy | 1 | 2011 | 703 | 0.260 |
Why?
|
| Thrombosis | 3 | 2021 | 2944 | 0.250 |
Why?
|
| Ventricular Fibrillation | 1 | 2008 | 537 | 0.240 |
Why?
|
| Uric Acid | 1 | 2011 | 807 | 0.240 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 1492 | 0.230 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 2247 | 0.230 |
Why?
|
| Lymphocytes | 1 | 2012 | 2603 | 0.230 |
Why?
|
| Vascular Patency | 2 | 2005 | 911 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2022 | 10218 | 0.220 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2003 | 48 | 0.220 |
Why?
|
| Pyrroles | 1 | 2009 | 1124 | 0.220 |
Why?
|
| Pulsatile Flow | 1 | 2004 | 320 | 0.210 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2004 | 1162 | 0.200 |
Why?
|
| Registries | 4 | 2021 | 8247 | 0.200 |
Why?
|
| Middle Aged | 30 | 2021 | 220853 | 0.200 |
Why?
|
| Coronary Stenosis | 2 | 2005 | 802 | 0.190 |
Why?
|
| Double-Blind Method | 8 | 2017 | 12341 | 0.180 |
Why?
|
| Heparin | 1 | 2008 | 1632 | 0.180 |
Why?
|
| Emergency Medical Services | 2 | 2011 | 1920 | 0.180 |
Why?
|
| Humans | 56 | 2024 | 761208 | 0.170 |
Why?
|
| Ischemia | 1 | 2008 | 1889 | 0.170 |
Why?
|
| Creatine Kinase | 1 | 2002 | 684 | 0.170 |
Why?
|
| Male | 31 | 2021 | 360693 | 0.160 |
Why?
|
| Neutrophils | 1 | 2012 | 3763 | 0.160 |
Why?
|
| Antithrombins | 3 | 2016 | 294 | 0.160 |
Why?
|
| Blood Platelets | 1 | 2010 | 2477 | 0.160 |
Why?
|
| Tachycardia, Ventricular | 1 | 2008 | 1305 | 0.160 |
Why?
|
| Female | 31 | 2021 | 392544 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 2270 | 0.150 |
Why?
|
| Aged | 22 | 2021 | 169288 | 0.150 |
Why?
|
| Tyrosine | 1 | 2002 | 1422 | 0.150 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 39126 | 0.140 |
Why?
|
| Postoperative Hemorrhage | 1 | 2021 | 416 | 0.140 |
Why?
|
| Isoenzymes | 1 | 2002 | 1682 | 0.140 |
Why?
|
| Prospective Studies | 7 | 2016 | 54435 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 9187 | 0.130 |
Why?
|
| Secondary Prevention | 4 | 2016 | 1472 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 10756 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 3245 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2017 | 15637 | 0.120 |
Why?
|
| Coronary Disease | 2 | 2013 | 5921 | 0.110 |
Why?
|
| Prognosis | 6 | 2021 | 29687 | 0.100 |
Why?
|
| Angina, Unstable | 2 | 2008 | 890 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 628 | 0.100 |
Why?
|
| Turkey | 1 | 2011 | 254 | 0.090 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2011 | 221 | 0.090 |
Why?
|
| Transportation of Patients | 1 | 2011 | 174 | 0.090 |
Why?
|
| Coronary Vessels | 1 | 2002 | 3111 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2017 | 4015 | 0.090 |
Why?
|
| Injections, Intra-Arterial | 1 | 2010 | 181 | 0.090 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 781 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 3821 | 0.090 |
Why?
|
| Hirudins | 1 | 2011 | 179 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2021 | 24021 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 12052 | 0.080 |
Why?
|
| Time and Motion Studies | 1 | 2008 | 143 | 0.080 |
Why?
|
| Time Factors | 7 | 2021 | 39957 | 0.080 |
Why?
|
| Drug Dosage Calculations | 1 | 2008 | 117 | 0.080 |
Why?
|
| Blood Flow Velocity | 2 | 2002 | 1375 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2011 | 590 | 0.070 |
Why?
|
| Contrast Media | 1 | 2001 | 5311 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 1376 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2008 | 4851 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 2576 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 788 | 0.070 |
Why?
|
| Survival Rate | 3 | 2017 | 12728 | 0.070 |
Why?
|
| Neuralgia | 1 | 2013 | 612 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2002 | 2854 | 0.070 |
Why?
|
| Nerve Block | 1 | 2013 | 706 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2928 | 0.070 |
Why?
|
| Embolism | 1 | 2010 | 399 | 0.070 |
Why?
|
| Comorbidity | 2 | 2012 | 10516 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2013 | 1496 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2011 | 10088 | 0.060 |
Why?
|
| Incidence | 4 | 2021 | 21365 | 0.060 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 1498 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 2217 | 0.060 |
Why?
|
| Hospitalization | 1 | 2024 | 10707 | 0.060 |
Why?
|
| Efficiency, Organizational | 1 | 2008 | 695 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 15520 | 0.060 |
Why?
|
| Plasminogen Activators | 1 | 2004 | 199 | 0.060 |
Why?
|
| Coronary Artery Bypass | 2 | 2022 | 2193 | 0.060 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2011 | 1061 | 0.060 |
Why?
|
| Stroke | 2 | 2022 | 9721 | 0.050 |
Why?
|
| Adult | 7 | 2016 | 221119 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2220 | 0.050 |
Why?
|
| Medicare | 1 | 2021 | 6773 | 0.050 |
Why?
|
| Atherectomy | 1 | 2002 | 42 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2012 | 6345 | 0.050 |
Why?
|
| Recurrence | 2 | 2006 | 8457 | 0.050 |
Why?
|
| Cardiology | 1 | 2013 | 1693 | 0.050 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2002 | 202 | 0.050 |
Why?
|
| Pyridines | 1 | 2013 | 2872 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 6504 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 2002 | 293 | 0.050 |
Why?
|
| Adolescent | 3 | 2016 | 88298 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2013 | 3923 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2014 | 80674 | 0.040 |
Why?
|
| Echocardiography | 1 | 2013 | 5006 | 0.040 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2001 | 335 | 0.040 |
Why?
|
| Exercise Test | 1 | 2007 | 2165 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 12976 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2004 | 1241 | 0.040 |
Why?
|
| Patient Selection | 1 | 2011 | 4246 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2011 | 5103 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 6819 | 0.040 |
Why?
|
| Fishes | 1 | 2021 | 600 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2004 | 1504 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 983 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2004 | 2359 | 0.040 |
Why?
|
| Pericardium | 1 | 2002 | 674 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6486 | 0.040 |
Why?
|
| Young Adult | 2 | 2016 | 59221 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 3418 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8519 | 0.030 |
Why?
|
| History, Ancient | 1 | 2016 | 213 | 0.030 |
Why?
|
| United States | 4 | 2021 | 72339 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 7400 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 15308 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 1664 | 0.030 |
Why?
|
| Risk Factors | 4 | 2013 | 74239 | 0.030 |
Why?
|
| Equipment Design | 1 | 2003 | 3510 | 0.030 |
Why?
|
| Research Design | 1 | 2011 | 6180 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 1901 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2002 | 6223 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 12474 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 3691 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 5842 | 0.030 |
Why?
|
| Heart Rate | 1 | 2004 | 4197 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 2223 | 0.020 |
Why?
|
| Linear Models | 1 | 2002 | 5869 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 15841 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2016 | 1567 | 0.020 |
Why?
|
| Mortality | 1 | 2021 | 2896 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 41496 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2016 | 2765 | 0.020 |
Why?
|
| Hospitals | 1 | 2021 | 3881 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2001 | 5521 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1423 | 0.020 |
Why?
|
| Cause of Death | 1 | 2017 | 3688 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 1506 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 1528 | 0.020 |
Why?
|
| Pandemics | 1 | 2024 | 8663 | 0.010 |
Why?
|
| Heart Failure | 1 | 2008 | 11701 | 0.010 |
Why?
|
| Consensus | 1 | 2013 | 3134 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 13249 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 58952 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 168079 | 0.010 |
Why?
|
Concepts
(195)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(15)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_